GSK claims Amgen v Sanofi decision “threatens” innovation

29-04-2021

Alex Baldwin

GSK claims Amgen v Sanofi decision “threatens” innovation

MAXSHOT.PL / Shutterstock.com

GlaxoSmithKline (GSK) has submitted an amicus brief to the Court of Appeals for the Federal Circuit claiming that the ruling on Amgen v Sanofi could “threaten incentives to invest in future discoveries.”


GSK, Amgen,Sanofi, Federal Circuit

LSIPR